1. Home
  2. PSTV vs PRPO Comparison

PSTV vs PRPO Comparison

Compare PSTV & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • PRPO
  • Stock Information
  • Founded
  • PSTV 1996
  • PRPO N/A
  • Country
  • PSTV United States
  • PRPO United States
  • Employees
  • PSTV N/A
  • PRPO 57
  • Industry
  • PSTV Medical/Dental Instruments
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PSTV Health Care
  • PRPO Industrials
  • Exchange
  • PSTV Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • PSTV 9.4M
  • PRPO 9.5M
  • IPO Year
  • PSTV N/A
  • PRPO N/A
  • Fundamental
  • Price
  • PSTV $1.41
  • PRPO $6.59
  • Analyst Decision
  • PSTV Strong Buy
  • PRPO
  • Analyst Count
  • PSTV 2
  • PRPO 0
  • Target Price
  • PSTV $14.00
  • PRPO N/A
  • AVG Volume (30 Days)
  • PSTV 84.6K
  • PRPO 7.9K
  • Earning Date
  • PSTV 10-29-2024
  • PRPO 11-11-2024
  • Dividend Yield
  • PSTV N/A
  • PRPO N/A
  • EPS Growth
  • PSTV N/A
  • PRPO N/A
  • EPS
  • PSTV N/A
  • PRPO N/A
  • Revenue
  • PSTV $5,509,000.00
  • PRPO $16,719,999.00
  • Revenue This Year
  • PSTV $11.13
  • PRPO $75.18
  • Revenue Next Year
  • PSTV N/A
  • PRPO N/A
  • P/E Ratio
  • PSTV N/A
  • PRPO N/A
  • Revenue Growth
  • PSTV 113.20
  • PRPO 52.61
  • 52 Week Low
  • PSTV $0.97
  • PRPO $4.31
  • 52 Week High
  • PSTV $2.78
  • PRPO $8.99
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 46.79
  • PRPO 52.82
  • Support Level
  • PSTV $1.20
  • PRPO $6.42
  • Resistance Level
  • PSTV $1.45
  • PRPO $6.99
  • Average True Range (ATR)
  • PSTV 0.10
  • PRPO 0.33
  • MACD
  • PSTV 0.01
  • PRPO -0.04
  • Stochastic Oscillator
  • PSTV 57.37
  • PRPO 69.91

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: